Morschhauser, Franck <br/><br/>
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).  [electronic resource] 

 -  Cancer  Sep 2010 
 - 4299-308 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.25280  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Drug Administration Schedule<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Lymphoma, Follicular--drug therapy<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Neoplasms, Second Primary--epidemiology<br/>Recurrence<br/>Rituximab<br/>Tumor Burden<br/>Vidarabine--administration & dosage